DE602004031772D1 - Anti-ip-10-antikörper - Google Patents

Anti-ip-10-antikörper

Info

Publication number
DE602004031772D1
DE602004031772D1 DE602004031772T DE602004031772T DE602004031772D1 DE 602004031772 D1 DE602004031772 D1 DE 602004031772D1 DE 602004031772 T DE602004031772 T DE 602004031772T DE 602004031772 T DE602004031772 T DE 602004031772T DE 602004031772 D1 DE602004031772 D1 DE 602004031772D1
Authority
DE
Germany
Prior art keywords
antibodies
present
directed
subject
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004031772T
Other languages
English (en)
Inventor
Balaji Balasa
Naoya Tsurushita
Nicolas F Landolfi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotherapeutics Inc
Original Assignee
Abbott Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/014507 external-priority patent/WO2004101511A2/en
Application filed by Abbott Biotherapeutics Corp filed Critical Abbott Biotherapeutics Corp
Priority claimed from PCT/US2004/037600 external-priority patent/WO2005060457A2/en
Publication of DE602004031772D1 publication Critical patent/DE602004031772D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/30—Hydrogen technology
    • Y02E60/32—Hydrogen storage
DE602004031772T 2003-12-04 2004-11-10 Anti-ip-10-antikörper Active DE602004031772D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52788203P 2003-12-04 2003-12-04
PCT/US2004/014507 WO2004101511A2 (en) 2003-05-09 2004-05-07 Anti-ip-10 antibodies and methods of using thereof for the treatment of inflamatory bowel diseases
PCT/US2004/037600 WO2005060457A2 (en) 2003-12-04 2004-11-10 Treatment of inflammatory bowel diseases with anti-ip-10 antibodies

Publications (1)

Publication Number Publication Date
DE602004031772D1 true DE602004031772D1 (de) 2011-04-21

Family

ID=43646212

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004031772T Active DE602004031772D1 (de) 2003-12-04 2004-11-10 Anti-ip-10-antikörper

Country Status (3)

Country Link
US (1) US7935793B2 (de)
AT (1) ATE501173T1 (de)
DE (1) DE602004031772D1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102838675B (zh) 2003-12-10 2014-07-30 梅达雷克斯有限责任公司 Ip-10抗体及其用途
AU2008219570B2 (en) 2007-02-28 2013-08-22 Novimmune Sa Human anti-IP-10 antibodies and uses thereof
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US20120321687A1 (en) * 2010-02-19 2012-12-20 University Of Virginia Patent Foundation Compositions and methods for using and identifying antimicrobial agents
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
AU2011320314B2 (en) * 2010-10-29 2015-08-06 Immunogen, Inc. Novel EGFR-binding molecules and immunoconjugates thereof
BR112013027867A2 (pt) 2011-04-29 2016-09-06 Bristol Myers Squibb Co "método de detectar o nível de um anticorpo anti-ip10 em amostra, anticorpo monoclonal isolado ou porção de ligação de antígeno do mesmo, linhagem de célula de hibridoma e kit"
MX2014006087A (es) 2011-11-21 2014-08-01 Immunogen Inc Metodo de tratamiento de tumores que son resistentes a terapias contra el receptor del factor de crecimiento epidermico (egfr) con agentes citotoxicos conjugados con anticuerpos dirigidos contra el receptor del factor de crecimiento epidermico.
KR101452865B1 (ko) * 2012-09-17 2014-10-21 서울대학교산학협력단 신규한 ｉｐ－１０ 에피토프 및 이에 대한 항체
CN111320693B (zh) * 2015-09-08 2023-04-07 卫材R&D管理有限公司 抗EphA4抗体
EP3383903A1 (de) 2015-11-30 2018-10-10 Bristol-Myers Squibb Company Humane ip-10-antikörper und deren verwendung
CN110087530A (zh) 2016-12-07 2019-08-02 普罗根尼蒂公司 胃肠道检测方法、装置和系统
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
EP3883635A1 (de) 2018-11-19 2021-09-29 Progenity, Inc. Verfahren und vorrichtungen zur behandlung einer krankheit mit biotherapeutika
EP3870261B1 (de) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Einnehmbare vorrichtung zur abgabe eines therapeutischen mittels an den magen-darm-trakt
CN111339181B (zh) * 2020-02-10 2021-08-06 腾讯科技（深圳）有限公司 区块存储方法、装置、节点设备及存储介质
CN114656561B (zh) * 2022-03-05 2023-06-09 南京鼓楼医院 一种抗ip-10单克隆抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3246079A1 (de) 1982-12-13 1984-06-14 Umbach, Albert, 3436 Hessisch Lichtenau Schleifgeraet, insbesondere zum schleifen von zaehnen von kettensaegen
FR2556219B1 (fr) * 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
IT1181800B (it) * 1984-12-19 1987-09-30 Fercad Spa Affilatore a mola rotante particolarmente per seghe a catena per tronchi d'albero
US7297478B1 (en) * 2000-09-22 2007-11-20 Large Scale Biology Corporation Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules

Also Published As

Publication number Publication date
US20080063646A1 (en) 2008-03-13
ATE501173T1 (de) 2011-03-15
US7935793B2 (en) 2011-05-03

Similar Documents

Publication Publication Date Title
ATE501173T1 (de) Anti-ip-10-antikörper
HRP20191341T1 (hr) Protutijela koja vežu ljudski cgrp receptor
LTC2041177I2 (lt) Didelio giminingumo antikūnai prieš žmogaus IL-6 receptorių
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
HRP20191609T1 (hr) Protein
CY1113224T1 (el) Νεο αντισωμα αντι-ρlgf
SE0401601D0 (sv) Protofibril specific antibodies and uses thereof
BRPI0617485B8 (pt) anticorpo anti-il-13 humano isolado, composição farmacêutica e uso do referido anticorpo
WO2005012493A3 (en) Anti-cd19 antibodies
CY1118063T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΑΝΘΡΩΠ1ΝΗΣ IgE ΥΨΗΛΗΣ ΣΥΓΓΕΝΕΙΑΣ
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
PE20110801A1 (es) Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f
EA200870050A1 (ru) Анти-il-17-антитела
RS54393B1 (en) HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR
RU2008132968A (ru) Антитела к рецептору тимусного стромального лимфопоэтина
RS53984B1 (en) IP-10 ANTIBODIES AND THEIR USES
DK1425389T3 (da) Interleukin-15-(IL-15)-specifikke humane antistoffer
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
HRP20090527T1 (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
WO2005026209A3 (en) Monoclonal antibodies against hmgb1
MY144980A (en) Method for rapid detection of lymphatic filariasis
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
MX2009009194A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.